Sanofi Pasteur, Sutro team up on vaccine candidates

Sanofi Pasteur and Sutro Biopharma will hook up to produce two undisclosed vaccine candidates. A statement offered little insight to the details of the collaboration. "This collaboration highlights the potential value of Sutro's biochemical synthesis technology for the production of vaccines and provides additional validation of the benefits of our technology platform," William Newell, CEO of Sutro, said in a statement. "We are looking forward to expanding our expertise in protein expression into the field of vaccines with an established leader in the area." Release

Suggested Articles

BN will use its proprietary MVA-BN platform to develop a vaccine against three strains of the potentially deadly mosquito-borne virus.

BN's cancer vaccine CV301 is already under evaluation with Keytruda in NSCLC and with Tecentriq in bladder cancer.

The two new grants will support development of universal flu and malaria vaccines leveraging CureVac’s RNActive mRNA-based platform.